Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Future Pharmacology
Special Issues
Feature Papers in Future Pharmacology 2024
share announcement

Feature Papers in Future Pharmacology 2024

A special issue of Future Pharmacology (ISSN 2673-9879).

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1020

Special Issue Editor

Prof. Dr. Fabrizio Schifano

E-Mail Website
Guest Editor
Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, UK
Interests: psychopharmacology; addiction; drug misuse; new psychoactive substances
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As the founding Editor-in-Chief, I am pleased to announce the collection titled “Feature Papers in Future Pharmacology 2024”. This Feature Papers Special Issue aims to collect high-quality papers from excellent scholars around the world, which introduce new insights into the scientific development of pharmacological sciences. Both original research articles and comprehensive review papers are welcome. All articles published will immediately be made available worldwide under an open access license.

We are happy to accept the latest results on a range of issues including, but not limited to, the following:

  • Drug design and discovery;
  • Drug metabolism;
  • Molecular/biochemical/cellular pharmacology;
  • Clinical pharmacology;
  • Behavioural pharmacology;
  • Toxicology;
  • Pharmacogenetics/pharmacogenomics;
  • Biopharmaceuticals.

Prof. Dr. Fabrizio Schifano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug design and discovery
  • drug metabolism
  • molecular/biochemical/cellular pharmacology
  • clinical pharmacology
  • behavioural pharmacology
  • toxicology
  • pharmacogenetics/pharmacogenomics
  • biopharmaceuticals

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

25 pages, 1509 KiB  
Review
A Narrative Review of Pharmacotherapy of Glaucoma
by Shalini Virani and Parveen Rewri
Future Pharmacol. 2024, 4(2), 395-419; https://doi.org/10.3390/futurepharmacol4020022 - 27 May 2024
Viewed by 284
Abstract
Progressive loss of retinal ganglionic cells (RGC) causes degeneration of optic nerve axons, which leads to blindness in glaucoma. Elevated intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the management of glaucoma is centred on reducing the IOP, and drugs [...] Read more.
Progressive loss of retinal ganglionic cells (RGC) causes degeneration of optic nerve axons, which leads to blindness in glaucoma. Elevated intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the management of glaucoma is centred on reducing the IOP, and drugs in the form of topical drops are the first line of management. Drugs reduce IOP either by suppressing aqueous humour secretion or improving the aqueous humour outflow. Newer drugs added during the past three decades to the armamentarium of glaucoma treatment have targeted the aqueous outflow. With an evolving understanding of the pathogenesis of glaucoma, the role of 24-h IOP control and other IOP-independent risk factors affecting ocular blood flow and RGC toxicity is also being actively studied in clinical and pre-clinical models of glaucoma. The role of available drugs in controlling IOP over 24 h is being evaluated. Improvement of ocular blood flow and neuroprotection are seen as potential drug targets for preventing the loss of RGC. In this article, we review the pharmacotherapy of glaucoma based on current therapeutic principles. Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
►▼ Show Figures

Figure 1

28 pages, 1753 KiB  
Review
Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer’s and Parkinson’s Disease
by Antea Krsek and Lara Baticic
Future Pharmacol. 2024, 4(2), 352-379; https://doi.org/10.3390/futurepharmacol4020020 - 30 Apr 2024
Viewed by 521
Abstract
Neurodegenerative disorders entail a progressive loss of neurons in cerebral and peripheral tissues, coupled with the aggregation of proteins exhibiting altered physicochemical properties. Crucial to these conditions is the gradual degradation of the central nervous system, manifesting as impairments in mobility, aberrant behaviors, [...] Read more.
Neurodegenerative disorders entail a progressive loss of neurons in cerebral and peripheral tissues, coupled with the aggregation of proteins exhibiting altered physicochemical properties. Crucial to these conditions is the gradual degradation of the central nervous system, manifesting as impairments in mobility, aberrant behaviors, and cognitive deficits. Mechanisms such as proteotoxic stress, neuroinflammation, oxidative stress, and programmed cell death contribute to the ongoing dysfunction and demise of neurons. Presently, neurodegenerative diseases lack definitive cures, and available therapies primarily offer palliative relief. The integration of nanotechnology into medical practices has significantly augmented both treatment efficacy and diagnostic capabilities. Nanoparticles, capable of traversing the blood–brain barrier, hold considerable potential for diagnosing and treating brain pathologies. By combining gene therapy with nanotechnology, the therapeutic effectiveness against neurodegenerative diseases can be substantially enhanced. Recent advancements in nano-biomaterial-based methodologies have fortified existing approaches to neural stem cell (NSC) differentiation therapies. NSC-targeting technologies offer a promising, potentially safe method for treating neurodegenerative diseases. This review endeavors to summarize current insights and perspectives on nanotechnology-driven therapeutic innovations in neurodegenerative disorders, with a particular emphasis on Alzheimer’s and Parkinson’s disease. Full article
(This article belongs to the Special Issue Feature Papers in Future Pharmacology 2024)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop